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Recent improvements in the prognosis of patients with esophageal cancer have 
led to the increased occurrence of gastric tube cancer (GTC) in the reconstructed 
gastric tube. However, there are few reports on the treatment results of 
endoscopic submucosal dissection (ESD) for GTC.
AIM 
To evaluate the efficacy and safety of ESD for GTC after esophagectomy in a 
multicenter trial.
METHODS 
We retrospectively investigated 48 GTC lesions in 38 consecutive patients with 
GTC in the reconstructed gastric tube after esophagectomy who had undergone 
ESD between January 2005 and December 2019 at 8 institutions participating in 
the Okayama Gut Study group. The clinical indications of ESD for early gastric 
cancer were similarly applied for GTC after esophagectomy. ESD specimens were 
evaluated in 2-mm slices according to the Japanese Classification of Gastric 
Carcinoma with curability assessments divided into curative and non-curative 
resection based on the Gastric Cancer Treatment Guidelines. Patient 
characteristics, treatment results, clinical course, and treatment outcomes were 
analyzed.
RESULTS 
The median age of patients was 71.5 years (range, 57-84years), and there were 34 
men and 4 women. The median observation period after ESD was 884 d (range, 8-
4040 d). The median procedure time was 81 min (range, 29-334 min), the en bloc 
resection rate was 91.7% (44/48), and the curative resection rate was 79% (38/48). 
Complications during ESD were seen in 4% (2/48) of case, and those after ESD 
were seen in 10% (5/48) of case. The survival rate at 5 years was 59.5%. During 
the observation period after ESD, 10 patients died of other diseases. Although 
there were differences in the procedure time between institutions, a multivariate 
analysis showed that tumor size was the only factor associated with prolonged 
procedure time.
CONCLUSION 
ESD for GTC after esophagectomy was shown to be safe and effective.
Key Words: Endoscopic submucosal dissection; Gastric tube; Gastric cancer; Eso-
phagectomy; Multicenter study; Retrospective study
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Despite increasing occurrence of gastric tube cancer (GTC) after 
esophagectomy, there are few reports on the treatment results of endoscopic 
submucosal dissection (ESD) for GTC. This multicenter study showed that treatment 
results and complications of ESD for GTC were similar to those of standard ESD and 
there were not significantly difference between institutions except for procedure time. 
ESD for GTC after esophagectomy is a safe and effective treatment.
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INTRODUCTION
Recently, the survival of patients with esophageal cancer after esophagectomy has 
improved[1-5]. However, the risk of a subsequent occurrence of primary cancer is high 
in these patients. The most frequent cancer that overlaps with esophageal cancer is 
head and neck cancer, while the second most common is gastric cancer, including 
gastric tube cancer (GTC)[6-9]. Therefore, the improved prognosis of esophageal cancer 
patients has led to an increase in the occurrence of GTC in the reconstructed gastric 
tube.
For the treatment of GTC after esophagectomy, total gastric tube resection (TGTR) 
or partial gastric tube resection (PGTR) has been proposed. However, surgical 
resection for GTC, being a secondary operation following esophagectomy, may lead to 
high mortality and morbidity[10,11]. On the other hand, in recent years, endoscopic 
therapy for early gastric cancer (EGC) has developed and become widespread[12]. 
Endoscopic submucosal dissection (ESD) enables the treatment of large lesions with a 
higher rate of en bloc resection that cannot be achieved by using conventional 
endoscopic mucosal resection. In addition, ESD is less invasive than surgery. For this 
reason, ESD has become widely used as a standard treatment for EGC, and ESD is 
often performed for GTC.
However, ESD for GTC after esophagectomy is a technically difficult procedure 
compared with that for an unresected stomach because of the limited working space, 
unusual fluid-pooling area, food residue, bile reflux, fibrosis, and staples under the 
suture line[13]. Therefore, a high degree of skill is required for ESD of GTC. There are 
few reports about ESD for GTC after esophagectomy, and most are case reports and 
case series of a small number of patients[13-17]. A study by Nonaka et al[18] reported the 
effectiveness and safety of ESD for GTC in a high-volume national center, which had 
largest number of cases but was nonetheless a single-center study. Therefore, the aim 
of this study was to evaluate the efficacy and safety of ESD for GTC after 
esophagectomy in a multicenter context.
MATERIALS AND METHODS
Patients
We retrospectively investigated patients with GTC in the reconstructed gastric tube 
after esophagectomy for esophageal squamous cell carcinoma who had undergone 
ESD between January 2005 and December 2019 at 8 institutions participating in the 
Okayama Gut Study group (O-GUTS). All of the participating institutions in O-GUTS, 
except Okayama University Hospital (OUH), were considered core hospitals in each 
area. During the study period, 48 GTC lesions in 38 consecutive patients were treated. 
The clinical indications of ESD for EGC were based on the Gastric Cancer Treatment 
Guidelines[19]. These indications were similarly applied for GTC after esophagectomy 
with gastric tube reconstruction.
Study measurements were as follows: patient characteristics, endoscopic findings, 
treatment results, adverse events, histopathological results, and clinical courses. In 
addition, we defined OUH as a high-volume center and compared the patients’ 
background and clinical outcomes between OUH and other facilities.
The institutional review board of each hospital approved this study, and informed 
consent was obtained from all patients.
Endoscopic procedures
All endoscopic procedures were performed by experts in ESD who had experience 
with more than 500 clinical cases. There were no restrictions on the scopes and devices 
used by each endoscopist for ESD. The scopes used were GIF-Q260J or GIF-H260 
(Olympus, Tokyo, Japan), and the devices were an insulation-tipped diathermic knife 
(IT Knife), IT Knife 2, IT Knife nano, or Dual Knife J (Olympus, Tokyo, Japan). Other 
devices, such as an argon plasma coagulation probe (ERBE, Tubingen, Germany) for 
marking dots or a needle knife (ZEON MEDICAL, Tokyo, Japan) for the initial 
incision, were occasionally used.
First, marking dots for the incision lines were placed around the lesion. Next, 
fructose-added glycerol (Glyceol; TAIYO Pharma CO, Tokyo, Japan) with a minute 
amount of indigo carmine dye was injected into the submucosal layer. In some cases, 
0.4% sodium hyaluronate (MucoUp; Boston Scientific, Tokyo, Japan) was used. After 
submucosal injection, a precut was made with the Dual Knife J or needle knife, 
followed by a circumferential mucosal incision around the lesion using the dots as a 
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landmark and submucosal dissection with the IT Knife, IT Knife 2, IT Knife nano, or 
Dual Knife J. The resected specimens were evaluated pathologically.
Histopathological assessment of curability
ESD specimens were evaluated in 2-mm slices according to the Japanese Classification 
of Gastric Carcinoma with curability assessments divided into curative and non-
curative resection based on the Gastric Cancer Treatment Guidelines[20]. R0 resection 
indicated that the lesion was resected en bloc with both the horizontal and vertical 
margins tumor-free histopathologically, but did not include findings regarding 
lymphovascular infiltration, the type of adenocarcinoma, or an assessment of the 
depth of invasion for curability. A curative resection was divided into eCura A and 
eCura B. A non-curative resection was defined as not meeting the criteria of curative 
resection and was further separated into 2 groups, eCura C-1 and eCura C-2, based on 
histopathological results per the Gastric Cancer Treatment Guidelines[19].
Statistical analysis
Continuous and categorical variables are expressed as median (range) and n (%), 
respectively. Overall survival was calculated according to the Kaplan-Meier method. 
Differences in the clinical outcomes of ESD for GTC between institutions were 
evaluated using the Mann-Whitney U test for continuous data and the Chi-squared 
test for categorical variables. The risk factors for long procedure time were evaluated 
using logistic regression analysis. All statistical analyses were performed using the 
statistical analysis software JMP Pro, version 15 (SAS Institute Inc., Cary, NC, United 
States). P values < 0.05 were considered statistically significant.
RESULTS
Patients’ characteristics and endoscopic findings
A total of 38 consecutive patients with 48 GTC lesions were treated with ESD between 
January 2005 and December 2019 (Table 1). The median age of these patients was 71.5 
years (range, 57-84 years), and they included 34 men and 4 women. The median period 
from esophagectomy to the treatment of GTC was 2106 d (range, 38-9523 d). This 
included patients who had a diagnosis of EGC before surgery for esophageal cancer 
and had undergone ESD after esophagectomy (5 patients). The reconstruction routes 
were antethoracic, retrosternal, and posterior mediastinal in 7, 11, and 20 patients, 
respectively. The location of the GTC lesion was upper, middle, and low in 2, 18, and 
28 patients, respectively. Regarding the macroscopic type, there were 21 lesions of 0-
IIa, 22 lesions of 0-IIc, 2 lesions of 0-IIb, 1 lesion of 0-III, and 2 combined lesions. The 
median observation period after ESD was 884 d (range, 8-4040 d).
Treatment results of ESD and histopathological findings
Treatment results of ESD for GTC after esophagectomy and pathological findings are 
shown in Table 2. The median procedure time was 81 min (range, 29-334 min). En bloc 
resection was performed in 44 of 48 lesions (91.7%). The median tumor size of the 
resected specimen was 15 mm (range, 4-60 mm). Among the 48 lesions, 43 were 
differentiated (90%) and 5 were undifferentiated (10%). Regarding the tumor depth, 40 
lesions were intramucosal carcinoma (M, 84%), 4 were submucosal superficial 
carcinoma (SM1, 8%), and 4 were submucosal deep invasive carcinoma (SM2 or 
deeper, 8%). Ulcerative findings were seen in 6 lesions (13%). Lymphatic infiltration 
was seen in 3 lesions (6%), and vascular infiltration was seen in 1 lesion (2%). 
According to the Japanese Gastric Cancer Treatment Guidelines, 38 lesions (79%) 
achieved curative resection (eCura A) and 10 lesions (21%) were classified as non-
curative resection. The reasons for non-curative resection were as follows: 3 lesions 
were horizontal margin positive (HM1) or cutting into the lesion (eCura C-1), 2 were 
undifferentiated and showed SM invasion, 2 showed lymphatic infiltration, 2 showed 
SM invasion with ulcerative findings, and 1 was undifferentiated and showed SM 
invasion and lymphatic and vascular infiltration (eCura C-2).
Adverse events
Complications during ESD were seen in 2 cases (4%), with 1 case of perforation, and 1 
case of bleeding. Complications after ESD were seen in 5 cases (10%), with 2 cases of 
bleeding, 1 case of subcutaneous abscess, 1 case of liver failure, and 1 case of 
respiratory failure (Table 2).
Satomi T et al. ESD for gastric tube cancer
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Table 1 Patients’ characteristics and endoscopic findings
Characteristics
Patients/lesions, n 38/48




Median period from esophagectomy to ESD for GTC, d (range) 2106 (38-9523)
Reconstruction route of gastric tube, n (%)
Antethoracic 7 (18)
Retrosternal 11 (29)
Posterior mediastinal 20 (53)
Median observation period after ESD, d (range) 884 (8-4040)










ESD: Endoscopic submucosal dissection; GTC: Gastric tube cancer; U: Upper; M: Medium; L: Lower.
It was the same patient who had perforation during ESD and who formed 
subcutaneous abscess after ESD (Figure 1). In this case, perforation during ESD was 
sealed immediately with endoclips. Nevertheless, 20 d after ESD, the patient was 
admitted to the hospital with redness of the skin in the precordial area and excretion of 
pus from the skin. Computed tomography showed formation of a subcutaneous 
abscess around the gastric tube of the antethoracic reconstruction route. The patient 
was treated conservatively with antibiotics and percutaneous drainage and was 
discharged on the 16th day after the start of re-admission.
Patients’ clinical courses
Of the 38 cases, 2 had local recurrence and 3 had metachronous recurrence. In the 2 
cases with local recurrence, 1 received additional surgery and the other received 
additional ESD. In the 3 cases with metachronous recurrence, 1 received additional 
surgery and the others received additional ESD. The patients’ overall survival curve is 
shown in Figure 2. The survival rate at 5 years was 59.5%. During the observation 
period after ESD, no patient died of GTC. However, 10 patients died of other diseases, 
including pneumonia, which was the most common and occurred in 4 patients, heart 
failure and hepatocellular carcinoma in 1 patient each, and other unknown diseases.
Comparison of clinical outcomes
A comparison of the patients’ background and clinical outcomes between OUH and 
other hospitals is shown in Table 3. In terms of the patients’ backgrounds, the posterior 
mediastinal route was used as a reconstruction route in more cases at other hospitals. 
Treatment results were generally similar in both groups; however, procedure time was 
significantly longer at other hospitals.
Since there were differences in procedure time between institutions, we divided 
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Table 2 Treatment results of endoscopic submucosal dissection for gastric tube cancer and histopathological findings
Lesions, n 48
Median procedure time, min (range) 81 (29-334)
En bloc resection, n (%) 44 (91.7)
Adverse events during ESD, n (%)
Bleeding 1(2)
Perforation 1(2)
Adverse events post ESD, n (%)
Bleeding 2 (4)
Subcutaneous abscess 1 (2)
Liver failure 1 (2)
Respiratory failure 1 (2)



























ESD: Endoscopic submucosal dissection; M: Intramucosal; SM1: Submucosal superficial; SM2: Submucosal deep invasive.
patients into two groups, a short procedure time group (< 90 min) and a long 
procedure time group (≥ 90 min), and examined the factors affecting the procedure 
time. In univariate analysis (Table 4), the treatment institution and tumor size showed 
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Table 3 Comparison of clinical outcomes between Okayama University Hospital and other hospitals
Institution (patients/lesions) OUH (17/20) Other hospitals (21/28) P value
Median age, yr (range) 70 (57-83) 73 (58-84) 0.28
Male, n (%) 15 (88) 19 (79) 0.72
Reconstruction route of gastric tube, n < 0.01
Antethoracic 7 0
Retrosternal 7 4
Posterior mediastinal 3 17
Median tumor size, mm (range) 18 (8-60) 15 (4-40) 0.21
depth, M/SM, n 16/4 24/4 0.6
Ulcerative findings positive, n (%) 3 (15) 4 (14) 0.94
Median procedure time, min (range) 50 (20-180) 108 (32-334) < 0.01
En bloc resection, n (%) 19 (95) 25 (89) 0.48
Curative resection (eCura A or B), n (%) 17 (85) 21 (75) 0.4
Adverse events during ESD, n (%) 1 (5.0) 1 (3.6) 0.8
Adverse events post ESD, n (%) 3 (15) 2 (7.1) 0.37
OUH: Okayama University Hospital; ESD: Endoscopic submucosal dissection; M: Intramucosal; SM: Submucosal.
Table 4 Comparison of short (< 90 min) and long (≥ 90 min) procedure time groups
< 90 min, n = 26 ≥ 90 min, n = 22 P value
Okayama University Hospital/other hospitals, n 15/11 5/17 0.01
Reconstruction route of gastric tube, n
Antethoracic/retrosternal/posterior mediastinal 6/11/9 3/4/15 0.06
Location of lesion, n
U/L/M 0/8/18 2/10/10 0.08
Median tumor size, mm (range) 13 (4-26) 15 (6-60) 0.06
Tumor depth, n
M/SM 23/3 17/5 0.30
Ulcerative findings positive, n 2 5 0.14
U: Upper; M: Medium; L: Lower; M: Intramucosal; SM: Submucosal.
significant differences between the two groups. However, in multivariate analysis 
(Table 5), tumor size was the only factor associated with a long procedure time.
DISCUSSION
This study was the first multicenter study on ESD for GTC in the reconstructed gastric 
tube after esophagectomy, and it included the second largest number of patients. 
According to a systematic review of GTC after esophagectomy, there are two surgical 
options for the treatment of GTC: PGTR or TGTR plus lymphadenectomy with colon 
or jejunal reconstruction[21]. However, surgical treatment for GTC is highly invasive 
and carries a certain degree of risk. Sugiura et al[10] reported that 5 of 7 cases of TGTR 
had surgical complications (leakage) and 2 died. In addition, 1 of 3 cases of PTGR had 
fatal complications. Akita et al[11] reported that 1 of 5 cases of TGTR died of 
postoperative complications. On the other hand, in previous studies on ESD for GTC, 
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Table 5 Multivariate analysis about risk factors for a long procedure time of endoscopic submucosal dissection for gastric tube cancer
Risk ratio (95%CI) P value
Other hospitals 3.18 (0.59-19.6) NS
Posterior mediastinal route 3.18 (0.61-19.4) NS
Location of lesion, U/M 2.12 (0.52-8.84) NS
Median tumor size ≥ 20 mm 4.90 (1.09-29.6) 0.04
U: Upper; M: Medium; CI: Confidence interval.
the proportions of R0 resection and curative resection were 87.5%-92% and 65%-85%, 
respectively, and complications were seen in 12.5%-18% of patients[13-18]. In the present 
study, the proportions of R0 resection and curative resection were 91.7% and 79%, 
respectively, and complications were seen in 10%. Overall, the treatment results of 
ESD for GTC in this study were similar to those of previous studies. In a previous 
study on gastric ESD of the unresected stomach, the proportions of R0 resection, 
curative resections, and complications were 92%-94.9%, 80.4%-94.7%, and 5.9%-6.3%, 
respectively[22,23]. Furthermore, in gastric ESD of the remnant stomach after 
gastrectomy, the proportions of R0 resection, curative resection, and complications 
were 84.7%-85%, 70.9%-78%, and 2.8%-21.1%, respectively[24,25]. ESD for GTC was 
considered a minimally invasive, effective, and relatively safe treatment.
There are some points of note in GTC. First, detection of early GTC requires long-
term regular endoscopic surveillance after esophagectomy. GTC is often found long 
after esophagectomy; in some cases, GTC is detected after more than 10 years and the 
risk of metachronous GTC is high[15-18]. Second, GTC may be difficult to diagnose. The 
reasons are as follows: Food residue and bile reflux are often seen in the gastric tube, 
and the lumen of the gastric tube is long and narrow and can constrain endoscopic 
observation[13]. Therefore, it is necessary to pay attention to these points during 
endoscopy for patients with gastric tube reconstruction after esophagectomy. Third, 
when performing ESD for GTC, it is necessary to pay attention to complications 
specific to GTC. For example, in our study, a subcutaneous abscess formed after 
treatment in a case with perforation during ESD for GTC in the antethoracic 
reconstruction route. This case was cured by conservative treatment with antibiotics 
and percutaneous drainage. Moreover, Miyagi et al[26] reported that post-treatment 
precordial skin burns occurred in 5 of 8 patients with GTC in the antethoracic 
reconstruction route. In this report, all burns were diagnosed as first-degree burns 
based on the clinical classification of burn depth, developed on postoperative day 1-2, 
and took 4-7 d to heal.
In this study, since approximately half of the patients were treated at OUH, we 
defined it as a high-volume center and compared clinical outcomes with those of other 
institutions. As a result, there were no significant differences in the clinical outcomes 
of ESD between institutions. In addition, lesion size was the only factor related to long 
procedure time in multivariate analysis. We believe these results were attributable to 
the fact that all of the participating institutions specialized in gastrointestinal diseases 
with more than 500 cases of ESD for EGC. Moreover, ESD for GTC may have been 
performed by leading specialists given the relative rarity of GTC. For these reasons, 
ESD for GTC seems safe if performed by specialists with sufficient ESD experience.
Previously, not a few patients had complications or died of other diseases during 
the course after esophagectomy[27,28]. However, due to the widespread use of minimally 
invasive esophagectomy, such as thoracoscopic and laparoscopic surgery, the 
incidence of postoperative complications, including respiratory complications, has 
decreased and the general condition of patients after esophagectomy has improved in 
recent years[29-32]. With continued improvements in the prognosis of esophageal cancer, 
the number of cases of GTC after esophagectomy will likely increase in the future and 
the demand for ESD for GTC is expected to increase further.
There were several limitations to this study. First, as this was a retrospective study, 
the ESD indications and devices used for treatment were not standardized. However, 
treatment was performed according to the typical standards. Second, since data on 
Helicobacter pylori infection status were missing in some patients, the association 
between GTC and Helicobacter pylori could not be evaluated. Third, as some patients 
were observed for only a short time, the assessment of long-term prognosis after ESD 
for GTC was insufficient. Further follow-up studies are needed in the future.
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Figure 1 A case of subcutaneous abscess formation after perforation during endoscopic submucosal dissection for gastric tube cancer. 
A: Gastric tube cancer located at the anterior wall of gastric body; B: Marking dots were placed around the lesion, and endoscopic submucosal dissection (ESD) was 
performed as usual; C: Perforation occurred during ESD; D: Perforation was sealed immediately with 4 endoclips; E: Redness of the skin in the precordial area, 20 d 
after ESD; F: Computed tomography performed 20 d after ESD. A subcutaneous abscess (yellow arrow) had formed around the gastric tube of the antethoracic 
reconstruction route (orange arrow).
CONCLUSION
In conclusion, ESD for GTC after esophagectomy is a safe and effective treatment that 
can be performed without significant variability in treatment results at any specialized 
institution where standard gastric ESD can be performed with sufficient expertise. 
Further accumulation and follow-up of cases of GTC are necessary in the future.
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Recent improvements in the prognosis of patients with esophageal cancer have led to 
the increased occurrence of gastric tube cancer (GTC) in the reconstructed gastric tube.
Research motivation
There are few reports on the treatment results of endoscopic submucosal dissection 
(ESD) for GTC.
Research objectives
This retrospective study aimed to evaluate the efficacy and safety of ESD for GTC after 
esophagectomy in a multicenter trial.
Research methods
We retrospectively investigated 48 GTC lesions in 38 consecutive patients with GTC in 
the reconstructed gastric tube after esophagectomy who had undergone ESD between 
January 2005 and December 2019 at 8 institutions participating in the Okayama Gut 
Study group. Patient characteristics, treatment results, clinical course, and treatment 
outcomes were analyzed.
Research results
The median age of patients was 71.5 years (range, 57-84years), and there were 34 men 
and 4 women. The median observation period after ESD was 884 d (range, 8-4040 d). 
The median procedure time was 81 min (range, 29-334 min), the en bloc resection rate 
was 91.7% (44/48), and the curative resection rate was 79% (38/48). Complications 
during ESD were seen in 4% (2/48) of case, and those after ESD were seen in 10% 
(5/48) of case. The survival rate at 5 years was 59.5%. During the observation period 
after ESD, 10 patients died of other diseases. Although there were differences in the 
procedure time between institutions, a multivariate analysis showed that tumor size 
was the only factor associated with prolonged procedure time.
Research conclusions
ESD for GTC after esophagectomy was shown to be safe and effective.
Research perspectives
As some patients were observed for only a short time, the assessment of long-term 
prognosis after ESD for GTC was insufficient. Further accumulation and follow-up of 
cases of GTC are necessary in the future.
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